[Influence of cerebrolysin therapy on the dynamics of diabetic polyneuropathy symptoms].
60 patients with clinical features of symmetric diabetic polyneuropathy have been examined including 30 patients of main group who received cerebrolysin and 30 patients of control group treated with milgamma. The effectiveness of treatment was assessed by the dynamics of polyneuropathic disorders in scores on the Diabetic polyneuropathy scale and the NDS. Pain syndrome was measured with the VAS. The significant therapeutic effectiveness of cerebrolysin was revealed for some parameters measured.
Bogdanov
E I
EI
Sakovets
T G
TG
Gil'mullin
I F
IF
D000596:Amino Acids / Q000008:administration & dosage*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010147:Pain Measurement; D016896:Treatment Outcome
D000596:Amino Acids; D018696:Neuroprotective Agents; C006952:cerebrolysin